Bexsero: Indications, Dosage, Precautions, Adverse Effects
Россия
  • Россия
  • Украина

Bexsero - Product Information

Manufacture: GlaxoSmithKline
Country: Canada
Condition: Meningococcal Meningitis Prophylaxis
Class: Vaccine combinations
Form: Liquid solution, Intramuscular (IM), Intravenous (IV)
Ingredients: recombinant Neisseria meningitidis group B NHBA fusion protein, recombinant Neisseria meningitidis group B NadA protein, recombinant Neisseria meningitidis group B fHbp fusion protein, Outer Membrane Vesicles Neisseria meningitidis group B strain NZ98/254, Sodium chloride, histidine, sucrose, water for injections

Summary Product Information

Route of Administration Dosage Form / Strength Clinically Relevant Nonmedicinal Ingredients
Intramuscular injection Suspension for injection.
White opalescent liquid suspension.
Recombinant Neisseria meningitidis serogroup BNHBA fusion protein 50 μg1,2,3.

Recombinant Neisseria meningitidis serogroup B NadA protein 50 μg 1,2,3.

Recombinant Neisseria meningitidis serogroup B fHbp fusion protein 50 μg 1,2,3.

Outer membrane vesicles (OMV) from Neisseria meningitidis serogroup B strain NZ98/254 25 μg measured as amount of total protein containing the PorA P1.42.

1Produced in E. coli by recombinant DNA technology.
2Adsorbed on aluminum hydroxide (0.5 mg aluminum).
3NHBA (Neisseria Heparin Binding Antigen), NadA (Neisserial adhesin A), fHbp (factor H binding protein).
For a complete listing see Dosage Forms,
Composition and Packaging Section.

Description

BEXSERO is a liquid vaccine that contains three purified Neisseria meningitidis serogroup B protein antigens: NadA (Neisserial adhesin A) as a single protein, NHBA (Neisseria Heparin Binding Antigen) as a fusion protein, fHbp (factor H Binding Protein) as a fusion protein and PorA P1.4 as the main antigen of Outer Membrane Vesicles (OMV) derived from N. meningitidis serogroup B, strain NZ 98/254. These antigens are adsorbed on aluminum hydroxide. The sequences of the recombinant protein antigens are derived from the following N. meningitidis serogroup B strains: NHBA is derived from strain NZ 98/254 and is fused with accessory protein 953 derived from strain 2996; NadA is derived from strain 2996 and fHbp is derived from strain MC58 and is fused with accessory protein 936, derived from strain 2996. The OMV antigen is a suspension that consists of small, membranous spherical vesicles, or fragments of vesicles, in which the native complex antigen composition of the subcapsular cell surface of N. meningitidis serogroup B, strain NZ98/254 (B:4:P1.7-2,4) is highly conserved and contains outer membrane protein PorA P1.4 as the main antigen. The recombinant proteins are prepared by recombinant DNA technology using extrachromosomal expression plasmid vectors in Escherichia coli cells. The OMV antigen is produced by fermentation of N. meningitidis strain NZ98/254, followed by inactivation of the bacteria with deoxycholate, which also mediates vesicle formation.

Indications and Clinical Use

BEXSERO is indicated for active immunization of individuals from 2 months through 17 years old against invasive disease caused by N. meningitidis serogroup B strains.

As the expression of antigens included in the vaccine is epidemiologically variable in circulating group B strains, meningococci that express them at sufficient levels are predicted to be susceptible to killing by vaccine-elicited antibodies (see section ACTION AND CLINICAL PHARMACOLOGY).

Contraindications

BEXSERO should not be administered to individuals who are hypersensitive to this vaccine or to any ingredient in the formulation or components of the container closure.
For a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph.

Warnings and Precautions

General

As with any vaccine, vaccination with Bexsero may not protect all vaccine recipients. BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains.

The vaccine antigens present in BEXSERO are also expressed by meningococci belonging to serogroups other than serogroup B. However, protection against invasive meningococcal disease (IMD) caused by other serogroups has not been studied. Therefore, protection against IMD caused by other serogroups should not be assumed.

Do not inject intravascularly.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Anxiety‐related reactions, including vasovagal reactions (syncope), hyperventilation or tress‐related reactions may occur in association with vaccination as a psychogenic response to he needle injection (see section ADVERSE REACTIONS). It is important that procedures are in lace to avoid injury from fainting.

There are no data on the use of BEXSERO in patients with chronic medical conditions

As with all injectable pediatric vaccines, the potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

The tip cap of the syringe may contain natural rubber latex. Although the risk for developing allergic reactions is very small, health professional should consider the benefit-risk prior to administering this vaccine to subjects with known history of hypersensitivity to latex.

Kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present, kanamycin levels in the final vaccine are less than 0.01 micrograms per dose. The safe use of Bexsero in kanamycin-sensitive individuals has not been established.

Febrile Illness

As with many other vaccines, the physician should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of acetaminophen at the time of, and closely after vaccination, can reduce the incidence and intensity of post-vaccination febrile reactions in infants and children (less than 2 years of age).

Administration of BEXSERO should be postponed in subjects suffering from an acute severe febrile illness. However, the presence of a minor infection, such a cold, should not be a reason to defer vaccination.

Hematologic

This vaccine should not be given to individuals with thrombocytopenia, hemophilia or any coagulation disorder that would contraindicate intramuscular injection, unless the potential benefit clearly outweighs the risk of administration.

Immune

There are no data on the use of BEXSERO in subjects with impaired immune responsiveness. In immunocompromised individuals, vaccination may not result in a protective antibody response.

Sexual Function/Reproduction

There are no data on fertility in humans.
No effects on fertility were observed in female rabbits receiving BEXSERO pre-mating and during pregnancy.

Special Populations

Pregnant Women

Insufficient clinical data on exposed pregnancies are available.
The potential risk for pregnant humans is unknown. Nevertheless, vaccination should not be withheld when there is a clear risk of exposure to meningococcal infection.

Preclinical data

Based on reproductive toxicology data in rabbits, BEXSERO is not predicted to affect pregnancyand parturition, or to increase the risk of embryofetal abnormalities.

Nursing Women

No data are available. The benefit-risk ratio must be examined before making the decision to immunise during breast-feeding.

Preclinical data

In a rabbit study, no effects on postnatal development were observed in nursing offspring of vaccinated maternal animals through day 29 of lactation.

Pediatrics (< 2 Months of Age)

No data are available.

Individuals (> 17 Years of Age)

Limited safety and immunogenicity data are available in individuals from 18 to 50 years of age. The safety and immunogenicity of BEXSERO in individuals older than 50 years have not been established.

Geriatrics (> 65 Years of Age)

No data are available.

Adverse Reactions

Adverse Drug Reaction Overview

The incidence and severity of any local, systemic or other reactions were generally comparable in the BEXSERO groups across all studies in adolescents and adults, and in infants and children (less than 2 years of age).

The most frequent local and systemic adverse reactions after vaccination with BEXSERO observed in clinical trials were:

  • Adolescents and adults: local reactions - pain, erythema, induration;
    systemic reactions - malaise, headache, myalgia
  • Infants and children (less than 2 years of age): local reactions - tenderness, erythema, induration;
    systemic reactions - fever, irritability, unusual crying, sleepiness.

Adverse Drug Reactions in Clinical Trials

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in trials may not reflect the rates observed in practice, and should not be compared with the rates in the clinical trials of another vaccine. Adverse drug reaction information from clinical trials is useful for identifying vaccine-related adverse events and for approximating rates.

The characterization of the safety profile of BEXSERO is based on data from 8 studies, including 7 randomized controlled clinical trials with 6427 participants (from 2 months of age) who received BEXSERO.

Among BEXSERO recipients, 4843 were infants and children (less than 2 years of age), and 1584 were adolescents and adults (from 11 years of age), respectively. Of the subjects who received the primary infant series of BEXSERO, 1630 received an additional dose in the second year of life.

Data on solicited local (tenderness/pain, erythema, swelling and induration) and systemic adverse reactions (change in eating habits, sleepiness, irritability, unusual crying, vomiting, diarrhea, rash, fever ≥38°C in infants and children (less than 2 years of age); myalgia, arthralgia, nausea, malaise, headache and fever in adolescents and adults) were collected in clinical studies on the day of vaccination and for the following 6 days after vaccination (days 1-7 after vaccination). Most reactions were of a mild to moderate nature and resolved within 48 hours after vaccination with BEXSERO.

In clinical studies in infants, when BEXSERO was given alone, the frequency of fever was comparable to that associated with concomitant use of routine infant vaccines [Pneumococcal 7-valent Conjugate Vaccine, Diphtheria CRM197 Protein (Prevnar; Pfizer) and diphtheria, tetanus, acellular pertussis, hepatitis B recombinant (adsorbed), inactivated poliomyelitis and adsorbed conjugated Haemophilus influenzae type b vaccine (Infanrix hexa; GlaxoSmithKline Biologicals)]. Fever occurred more frequently when BEXSERO was co-administered with routine infant vaccines. Higher rates of antipyretic use were also reported for infants vaccinated with BEXSERO and routine vaccines. When fever occurred, it generally followed a predictable pattern, with the majority resolving within 48 hours after vaccination.

Solicited Adverse Reactions

Infants and Children (Less Than 2 Years of Age)

The characterization of the safety profile of BEXSERO in the infant and children (less than 2 years of age) populations was based primarily on data from 3 studies: V72P12 and V72P13 in infants 2 months of age, and V72P13E1 in children 12 to 13 months of age. In studies V72P12 and V72P13, the main schedule investigated was a three-dose primary series of BEXSERO administered at 2, 4 and 6 months of age. A three-dose accelerated schedule given at 2, 3 and 4 months of age was also evaluated in V72P12. BEXSERO was routinely administered with infant vaccines, Infanrix hexa and Prevnar, except for one group of subjects in study V72P12 who received BEXSERO alone at 2, 4 and 6 months of age and the routine vaccines at 3, 5 and 7 months of age. In study V72P13E1, which was an extension of V72P13, subjects who previously received BEXSERO at the 2, 4, 6-month schedule received a fourth dose of BEXSERO at 12 months of age; control subjects who received only the routine infant vaccines in V72P13 (vaccine naive) were vaccinated with a two-dose catch-up schedule of BEXSERO at either 12 and 14 or 13 and 15 months of age.

Data on local and systemic reactions after vaccination of infants with BEXSERO at 2, 4 and 6 months of age are shown in Table 1 and Table 2. Most of the reactions were transient and there was no clear trend of increasing frequency with subsequent doses. The reactogenicity profile was comparable for BEXSERO administered at the 2, 3, 4-month schedule

Fever (≥ 38 °C) was more frequently reported following vaccination with BEXSERO concomitantly with routine vaccines, compared with meningococcal C conjugate vaccine (Menjugate; Novartis) with concomitant routine vaccines, or routine vaccinations only (Table 2). The onset of fever in the majority of BEXSERO recipients occurred within 6 hours of vaccination and the duration of the fever was transient, resolving within 48 hours after vaccination. This pattern was consistent for all three BEXSERO doses. There was a trend for subjects to have a higher probability of developing fever at a subsequent dose of BEXSERO if the subject experienced fever at the preceding dose(s).

More subjects used antipyretics after vaccination with BEXSERO and routine vaccines simultaneously than did those vaccinated with either BEXSERO or routine vaccines alone (Table 2). Even though fever rates were higher in subjects vaccinated with BEXSERO and concomitant vaccines, rates for fever in which a medical visit was sought were low and comparable to recipients of Menjugate with routine vaccines and routine vaccines only (Table 2). Systemic reaction rates were comparable between the 2, 4, 6-month and 2, 3, 4-month schedules for recipients of BEXSERO with routine vaccines. For those subjects who received BEXSERO alone in the 2, 4, 6-month schedule without concomitant vaccines, fever rates were reduced (26% to 41% across the three doses) and comparable to the rates in subjects receiving only the routine infant vaccines.

Table 1 - Percentage of Infants Experiencing Local Reactions on Days 1-7 Following Vaccination with BEXSERO and Routine Vaccines (Infanrix hexa, Prevnar) at 2, 4, and 6 Months of Age
Percentage of Subjects With Injection Site Reactions (Severe or >100mma)
Dose BEXSERO Siteb Infanrix hexa Sitee Prevnar Sited
1 N=3101 N=3102 N=3102
2 N=3044 N=3047 N=3047
3 N=3019 N=3023 N=3022
Tenderness 1 66(14) 56(11) 54(11)
2 66(14) 57(11) 55(11)
3 65(14) 58(12) 56(11)
Erythema 1 60(<1) 46(0) 41(0)
2 63(0) 57(0) 49(0)
3 64(<1) 58(0) 52(0)
Induration 1 51(0) 33(0) 25(0)
2 54(0) 47(0) 35(0)
3 55(0) 49(0) 36(0)
Swelling 1 26(<1) 16(0) 13(0)
2 27(<1) 21(0) 17(0)
3 31(<1) 23(0) 19(0)

aSevere tenderness - cried when injected limb was moved; erythema, induration and swelling - >100 mm;

bBEXSERO: combined data of BEXSERO (studies V72P12 and V72P13) administered concomitantly with routine vaccines (Infanrix hexa, Prevnar) in a 2, 4, 6-month schedule;

cInfanrix hexa vaccine administered in a 2, 4, 6-month schedule (studies V72P12 and V72P13);

dPrevnar vaccine administered in a 2, 4, 6-month schedule (studies V72P12 and V72P13).

Table 2 - Percentage of Infants Experiencing Systemic Reactions on Days 1-7 Following Vaccination with BEXSERO and Routine Vaccines (Infanrix hexa, Prevnar) at 2, 4 and 6 Months of Age
Percentage of Subjects With Systemic (Severea)Reaction
Dose BEXSERO+Routine Vaccines Groupb Menjugate+Routine Vaccines Groupce Routine Vaccines Only Groupd
1 N=3102 N=490 N=659
2 N=3046-3048 N=478-479 N=654
3 N=3023-3024 N=470-471 N=651
Change Eat. Habits 1 51(3) 31(1) 30(2)
2 44(3) 32(1) 25(<1)
3 43(3) 29(1) 25(2)
Sleepiness 1 72(3) 58(4) 56(2)
2 64(2) 45(1) 42(<1)
3 53(1) 35(1) 32(<1)
Vomiting 1 13(1) 11(<1) 7(<1)
2 13(<1) 11(1) 6(<1)
3 12(<1) 9(<1) 7(<1)
Diarrhea 1 24(1) 20(1) 17(1)
2 22(1) 15(<1) 17(<1)
3 18(1) 13(1) 12(<1)
Irritability 1 79(6) 55(3) 61(2)
2 79(7) 58(4) 62(3)
3 76(6) 49(3) 54(1)
Unusual Crying 1 69(5) 52(3) 41(2)
2 66(5) 50(4) 40(2)
3 56(4) 39(3) 30(2)
Rash
(Urticarial)
1 5(1) 4(<1) 3(1)
2 6(2) 4(<1) 5(1)
3 5(1) 3(0) 5(1)
Other Solicited Outcomes
Fever ≥38°C
(≥40°C)
1 75(<1) 46(0) 44(<1)
2 79(1) 63(<1) 59(<1)
3 69(1) 42(0) 50(1)
Analgesic/
Antipyretic
Medication usef
1 75 40 43
2 81 52 52
3 71 36 45
Medically
Attended Feverg
1 1 1 1
2 1 1 <1
3 1 2 1

aDefinition of severe: change in eating habits-missed >2 feeds; sleepiness-sleeps most of the time, hard to arouse; vomiting-little/no intake for more prolonged time; diarrhea - ≥ 6 liquid stools, no solid consistency; Irritability-unable to console; Unusual crying-unusual, high pitched, screaming, unlike the child’s normal crying, that persists for ≥3 hours;

bBEXSERO+Routine Vaccines Group: combined data (studies V72P12 and V72P13) from BEXSERO administered concomitantly with routine vaccines (Infanrix hexa, Prevnar) at a 2, 4, 6-month schedule;

cMenjugate+Routine Vaccines Group: data from Menjugate administered concomitantly with routine vaccines (Infanrix hexa, Prevnar) from study V72P13 at a 2, 4, 6-month schedule;

dRoutine Vaccines Only Group: data from routine vaccines (Infanrix hexa, Prevnar) administered at a 2, 4, 6-month schedule from study V72P13;

eFever is based on actual temperature recorded with no adjustment for route of measurement.
Body temperature was measured mainly by the rectal route in study V72P13; in study V72P12 body temperature was measured by both the rectal and axillary routes (30-31% rectal, 58-61% axillary);

fPercentage of subjects who were treated with analgesic or antipyretic medication during the day 1-7 time period after study vaccination;

gPercentage of subjects who had fever for which a medical visit was sought during the day 1-7 time period after study vaccination.

In an additional study, V72P16, BEXSERO was administered with Infanrix hexa and Prevnar at 2, 3 and 4 months of age, with or without prophylactic acetaminophen. Data from this study showed that there is a statistically significant reduction in the percentage of subjects reporting fever both within 3 days and 7 days after vaccination when prophylactic acetaminophen treatment is adopted, without impacting the immune responses (see Part II, Immunogenicity Data).

Data on local and systemic reactions in children less than 2 years of age receiving either a fourth dose (booster) or two catch-up doses of BEXSERO are shown in Table 3 and Table 4. Additional data for a fourth dose of BEXSERO at 12 months of age in study V72P16 (after three doses at 2, 3 and 4 months of age) and at 12, 18 or 24 months of age in study V72P12E1 (after three doses at either 2, 4 and 6 months of age or 2, 3 and 4 months of age) confirmed these results. Data for a two-dose catch-up schedule of BEXSERO at either 12 and 14 or 18 and 20 months of age in control subjects who received only the routine infant vaccines in V72P12 are also in line with these observations.

In general, the majority of the local and systemic reactions following either a fourth dose or two-dose catch-up series of BEXSERO were transient, and most were mild or moderate in severity. Reactions (except tenderness) did not become more frequent after the second catch-up dose of BEXSERO.

Table 3 - Percentage of Children (less than 2 years of age) Experiencing Local Reactions on Days 1-7 Following Vaccination with a Fourth Dose of BEXSERO at 12 Months of Age or with Two Catch-Up Doses of BEXSERO at 13 and 15 or 12 and 14 Months of Age, With or Without Concomitant Priorix-Tetra
Percentage of Subjects With Injection Site Reactions (Severe or >50mma)
4th Dose of BEXSERO Two Catch-up Doses of BEXSERO
Schedule
BEXSERO with Priorix Tetra at 12 mos.







N=765

BEXSERO at 12mos.







N=789
Dose 1: Priorix-Tetra at 12 mos.

Dose 2: BEXSERO at 13 mos.

Dose 3: BEXSERO at 15 mos
N=28
Dose 1: BEXSERO with Priorix-Tetra at 12 mos.
Dose 2: BEXSERO at 14 mos.




N=117
Tenderness Dose
1

71(14)

71(15)

20(1)b

57(10)
2 - - 56(10) 67(18)
3 - - 66(16) -
Erythema 1 66(8) 68(7) 42(0)b 68(2)
2 - - 62(1) 60(2)
3 - - 58(3) -
Induration 1 51(4) 54(3) 19(0)b 68(2)
2 - - 40(<1) %46(<1)
3 - - 42(<1) -
Swelling 1 37(6) 36(5) 19(0)b 31(1)
2 - - 29(1) 28(1)
3 - - 30(3) -

aSevere tenderness-cried when injected limb was moved; erythema, induration and swelling - >50 mm;

bLocal reactions at the Priorix-Tetra injection site;
mos: months

Table 4 - Percentage of Children (less than 2 years of age) Experiencing Systemic Reactions on Days 1-7 Following Vaccination with a Fourth Dose of BEXSERO at 12 Months of Age or with Two Catch-Up Doses of BEXSERO at 13 and 15 or 12 and 14 Months of Age, With or Without Concomitant Priorix-Tetra
Percentage of Subjects With Systemic Reactions (Severea)
4th Dose of BEXSERO Two Catch-up Doses of BEXSERO
Schedule
BEXSERO with Priorix Tetra at 12 mos.






N=764-765

BEXSERO at 12mos.






N=789
Dose 1: Priorix-Tetra at 12 mos.

Dose 2: BEXSERO at 13 mos.
Dose 3: BEXSERO at 15 mos
N=274-284
Dose 1: BEXSERO with Priorix-Tetra at 12 mos.
Dose 2: BEXSERO at 14 mos.



N=116-117
Change in Eating Habits Dose
1

41(2)

40(2)

25(1)

38(0)
2 - - 34(1) 37(3)
3 - - 30(2) -
Sleepiness 1 47(1) 45(1) 30(<1)b 47(1)
2 - - 39(1) 41(0)
3 - - 39(1) -
Vomiting 1 7(<1) 5(<1) 7(0) 2(0)
2 - - 5(<1) 3(1)
3 - - 3(0) -
Diarrhea 1 25(1) 20(1) 16(1) 29(0)
2 - - 15(0) 22(0)
3 - - 15(0) -
Irritability 1 73(4) 68(3) 43(1) 70(3)
2 - - 60(2) 63(3)
3 - - 56(3) -
Unusual Crying 1 43(2) 37(2) 19(1) 35(2)
2 - - 28(1) 36(3)
3 - - 27(1) -
Rash (Urticarial) 1 7(3) 7(2) 7(3) 8(1)
2 - - 5(2) 3(2)
3 - - 4(1) -
Fever ≥38°C (≥40°C) 1 47(1) 41(<1) 24(<1) 46(0)
2 - - 37(0) 43(0)
3 - - 35(<1) -
Antipyretic Medication useb 1 57 51 23 57
2 - - 42 50
3 - - 39 -
Med. Attended Feverc 1 1 2 1 1
2 - - 0 2
3 - - 1 -

aDefinition of severe: change in eating habits-missed >2 feeds; sleepiness-sleeps most of the time, hard to arouse;vomiting-little/no intake for more prolonged time; diarrhea - ≥ 6 liquid stools, no solid consistency; Irritabilityunable to console; Unusual crying-unusual, high pitched, screaming, unlike the child’s normal crying, that persistsfor ≥3 hours;

b Percentage of subjects who were treated with any antipyretic medication during the day 1-7 time period after study vaccination;

c Percentage of subjects who had fever for which a medical visit was sought during the day 1-7 time period after study vaccination;
mos: months

Children (Aged 2 Years Through 10 Years)

The characterization of the safety profile of BEXSERO in this population is based on data from 4 studies in more than 290 subjects: V72P12E1 and V72P13E2 in children 24 months of age, V72P6E1 and V72P9E1 in children 40 to 60 months of age. In all these studies, the schedule investigated was a two-dose primary series of BEXSERO administered with an interval of 2 months between doses.

Data on local and systemic reactions following vaccination with BEXSERO in children 2 through 10 years of age are shown in Table 5 and Table 6. Most of the solicited reactions were mild or moderate in severity and transient. The percentages of subjects with fever ranged from 10% to 28% in this age group. These rates were lower with increasing age. Few children (0-3% of subjects) experienced body temperature ≥ 40°C. Fever associated with BEXSERO vaccination occurred early after vaccination, and was transient, with the majority resolving within 2 days. Medically attended fever events occurred in no more than 3% of children.

Table 5 - Percentage of Children (2 to 10 Years of Age) Experiencing Local Reactions on Days 1-7 Following Vaccination with BEXSERO
Percentages of Subjects With Any (Severe) Reaction
Age 24 to 26 months 40-44 months 60-62 months
Local Reaction Study Dose V72P12E1 (N=54) V72P13E2 (N=112) V72P6E1 (N=42) V72P9E1 (N=41) V72P9E1 (N=48)
Pain 1 - - 93(21) 87(8) 92(10)
2* - - 85(15) 95(24) 91(13)
Tenderness 1 87(26) 88(10) - - -
2* 81(35) 89(18) - - -
Erythema 1 72(2) 77(0) 98(0) 92(0) 94(0)
2* 60(0) 73(1) 93(0) 97(0) 87(0)
Induration 1 50(0) 49(0) 33(0) 44(0) 40(0)
2* 42(0) 56(0) 49(0) 49(0) 44(0)
Swelling 1 35(0) 31(0) 48(0) 26(0) 46(0)
2* 37(0) 39(0) 63(0) 41(0) 44(0)

*local reaction after second dose was evaluated in at least N=52 in study V72P12E1, N=108 in study V72P13E2, N=41 in study V72P6E1, N=37 in study V72P9E1 (40-44 months cohort) and N=45 in study V72P9E1 (60-62 months cohort).

Table 6 - Percentage of Children (2 to 10 Years of Age) Experiencing Systemic Reactions Days 1-7 Following Vaccination with BEXSERO
Age Percentages of Subjects With Any (Severe) Reaction
24 to 26 months 40-44 months 60-62 months
Systemic Reaction Study Dose V72P12E1 (N=54) V72P13E2 (N=112) V72P6E1 (N=42) V72P9E1 (N=39) V72P9E1 (N=48)
Change Eat. Habits 1 46(2) 34(0) 38(2) 33(3) 21(2)
2* 40(4) 36(3) 34(0) 35(3) 22(2)
Sleepiness 1 33(2) 46(0) 48(5) 51(8) 40(6)
2* 35(0) 46(3) 37(2) 46(8) 30(0)
Vomiting 1 11(2) 8(0) 2(0) 3(0) 10(0)
2* 8(2) 5(0) 0 11(0) 7(0)
Diarrhea 1 37(0) 13(0) 14(0) 5(0) 4(0)
2* 13(4) 12(0) 2(0) 5(0) 4(0)
Irritability 1 52(7) 59(2) 76(7) 62(0) 44(4)
2* 44(4) 58(5) 59(5) 62(5) 43(2)
Unusual Crying 1 28(2) 33(1) - - -
2* 29(4) 27(3) - - -
Headache 1 - - 10(0) 10(0) 13(2)
2* - - 10(2) 11(0) 20(0)
Arthralgia 1 - - 31(7) 23(3) 31(2)
2* - - 22(7) 19(5) 33(2)
Rash 1 4(0) 7(3) 2(2) 5(0) 6(0)
2* 0 6(0) 5(0) 3(0) 9(2)
Fever [Body Temp. ≥38°C (≥40°C)] 1 28(0) 21(0) 10(0) 15(3) 10(0)
2* 25(0) 26(1) 12(0) 11(0) 11(0)
Medical Attended Fever 1 2(-) 0(-) 0(-) 0(-) 0(-)
2* 0(-) 2(-) 0(-) 3(-) 0(-)

*systemic reaction after second dose was evaluated in at least N=52 in study V72P12E1, N=108 in study V72P13E2, N=41 in study V72P6E1, N=37 in study V72P9E1 (40-44 months cohort) and N=46 in study V72P9E1 (60-62 months cohort)

Adolescents (Aged 11 Years Through 17 Years)

The characterization of the safety profile of BEXSERO in the adolescent population aged 11 through 17 years was based on data from study V72P10.
One, two or three doses of BEXSERO were administered to adolescents according to one of the following schedules: 0, 0-1, 0-2 or 0-1-2 months.
The data supporting the safety and tolerability of the two-dose vaccination schedules for adolescents were generated from the first and second doses of the schedules investigated in this study.
Data on local and systemic reactions are shown in Table 7.

Reports of fever following BEXSERO vaccination were infrequent (3-4% across vaccinations) and were comparable to the rates observed in adolescents receiving placebo (2-4%).

The frequency of reports for local and systemic reactions did not increase with the second dose of BEXSERO, and the majority of the reactions were transient.

Additional safety data on BEXSERO in adolescents relative to the administration of one dose at month 6 from study V72P10 and for 2 doses 1 month apart in study V72_41 were in line with these observations

Table 7 - Percentage of Adolescents (aged 11-17 Years) Experiencing Local and Systemic Reactions on Days 1-7 Following Vaccination with BEXSERO
Percentages of Subjects With Any (Severea)Reaction
Study Schedule

Age
V72P10
(Combined Month 0, 0-1, 0-2)
11-17 years
Dose
1
2
BEXSERO
N=1503
N=1039
Placebob
N=128
N=124
Local Reactions
Erythema 1 54(<1) 40(0)
2 51(<1) 31(0)
Induration 1 40(<1) 27(0)
2 40(<1) 23(0)
Swelling 1 39(<1) 20(0)
2 38(1) 15(0)
Pain 1 91(17) 86(9)
2 85(15) 71(9)
Systemic Reactions
Malaise 1 56(7) 48(3)
2 50(7) 35(2)
Myalgia 1 45(7) 41(4)
2 40(6) 40(3)
Arthralgia 1 24(2) 19(0)
2 21(3) 16(1)
Headache 1 46(5) 37(2)
2 42(5) 33(3)
Nausea 1 19(1) 17(2)
2 16(2) 15(1)
Fever ≥38°C (≥40°C) 1 3(0) 4(0)
2 4(0) 2(0)
Other Solicited Outcomes
Analgesic/antipyretic usec 1 35 20
2 27 15
Stayed home due to reactiondc 1 16 6
2 11 3

aSevere erythema, induration and swelling - >100 mm; severe pain and systemic reactions - unable to perform normal daily activity;

bbPlacebo administered in month 0-1 schedule

cPercentage of subjects who were treated with analgesic or antipyretic medication during the day 1-7 time period after study vaccination;

dCollected as yes or no

Adults (Aged 18 Years Through 50 Years)

Limited safety data were collected in studies V72P5 (N=28) and V72P4 (N=53) in adults 18 to 40 and 18 to 50 years of age, respectively. The most commonly reported local reaction was pain, ranging from 82% to 98% across studies and two vaccine doses. The most commonly reported systemic reactions were malaise, myalgia and headache, ranging from 14% (malaise) to 57% (myalgia) across studies and two vaccine doses. Reports of fever following BEXSERO vaccination were infrequent (2-4%).

Unsolicited Adverse Events

Regardless of the age and of the vaccination schedule, there was no major difference in the percentages of subjects reporting unsolicited AEs (Adverse Events) within 1 month of the last vaccination or during the safety follow-up period between the BEXSERO given alone or in combination with routine vaccinations and comparator groups. Only a few AEs were assessed as possibly or probably related in the safety follow up period.

Infants and Children (Less Than 2 Years of Age)

Between study day 1 and 7 months of age (1 month after the third dose), the percent of subjects experiencing unsolicited AEs in the BEXSERO with concomitant routine vaccines, Menjugate with concomitant routine vaccines, and routine vaccines only groups are shown in Table 8. Overall, between study day 1 and 7 months of age, the most commonly reported AEs after any vaccination with BEXSERO were injection site reactions (most considered as possibly related to vaccination as these local reactions of induration, erythema, and swelling were solicited AEs continuing after the 7-day vaccination window) and upper respiratory tract infections (10%; mostly considered unrelated to vaccination).

Table 8 - Overview of Unsolicited Adverse Events of BEXSERO Administered with Concomitant Routine Vaccines at 2, 4 and 6 Months of Age, Collected From Study Day 1 to 7 Months of Age, by Vaccine Group
Percentage of Subjects with Adverse Events
BEXSERO+Routine Vaccines Groupa
N=3155
Menjugate+Routine Vaccines Groupb
N=488
Routine Vaccines Only Groupc
N=658
Any AEs 77 63 71
At least possibly related AEs 52 42 34
Serious AEs 4 3 3

aBEXSERO+Routine Vaccines Group: combined data (studies V72P6, V72P12 and V72P13) from BEXSERO administered concomitantly with routine vaccines (Infanrix hexa, Prevnar) at a 2, 4, 6-month schedule;

bMenjugate+Routine Vaccines Group: data from Menjugate administered concomitantly with routine vaccines (Infanrix hexa, Prevnar) at a 2, 4, 6-month schedule from study V72P13;

cRoutine Vaccines Only Group: data from routine vaccines (Infanrix hexa, Prevnar) administered at a 2, 4, 6-month schedule from study V72P13;
AEs: Adverse Events.

The percentage of subjects who experienced unsolicited AEs after a two-dose catch-up schedule of BEXSERO in vaccine naive children (in their second year of life) was 17% after the first dose and 15% after the second dose of the vaccine; 3% had AEs considered by the investigator to be at least possibly related to vaccination and <1% to 6% were considered serious. The most commonly reported AEs were local injection site reactions and systemic reactions that were originally solicited, but continued past day 7 after vaccination. All of the injection site reactions were at least possibly related to study vaccination. The percentage of subjects who experienced unsolicited AEs after the fourth dose of BEXSERO in the second year of life was 44% and 74% for subjects who received BEXSERO alone and those who received BEXSERO with concomitant Priorix-Tetra vaccine, respectively. The most commonly reported AE was injection site induration. Most of the other AEs were due to local injection site reactions and systemic reactions that were originally solicited, but continued past day 7 after the vaccination.

Children (Aged 2 Years Through 10 Years)

Data on unsolicited AEs in children 2-10 years of age are shown in Table 9.

Table 9 - Overview of Unsolicited Adverse Events in Children (2 to 10 Years of Age) After the Two-Dose Schedule of BEXSERO
Percentage of Subjects with Adverse Events
Age of subjects 24 to 26 months 40-44 months 60-62 months
Study V72P12E1 V72P13E2 V72P6E1 V72P9E1 V72P9E1
N=55 N=112 N=42 N=41 N=48
Any AEs 75 86 43 61 38
Possibly related 29 36 14 15 27
SAEs 2 5 2 10 2

Adolescents and Adults

Table 10 provides an overview of unsolicited AEs collected up to study Month 3 in adolescents and adults who received BEXSERO in either the 0-1 month or 0-2 month schedule.
SAEs (Serious Adverse Events) were not reported by any adult subjects. SAEs were infrequently reported (1%) in adolescents.

For both adolescents and adults, the most commonly reported possibly or probably related unsolicited AEs were local injection site reactions (pain, induration, swelling) that continued past the day 7 observation period.

Table 10 - Overview of Unsolicited Adverse Events Collected up to Month 3 in Adolescents and Adults (11 Years of Age and Older), after the Two-Dose Schedule of BEXSERO
Percentage of Subjects with Adverse Events
0-1 Month Schedulea 0-2 Month Scheduleb
11 to 17 yoa
N=748
18 to 40 yoa
N=28
11 to 17 yoa
N=380
18 to 50 yoa
N=53
Any AEs 43 18 46 32
Possibly or probably related AEs 17 4 16 13
Serious AEs 1 0 1 0

a0-1 schedule: BEXSERO was administered at months 0 and 1 in the 18 to 40 years of age (study V72P5) and at months 0 and 1 in the 11 to 17 years of age (study V72P10);

b0-2 schedule: BEXSERO was administered at months 0 and 2 in the 18 to 50 years of age (study V72P4) and at months 0 and 2 in the 11 to 17 years of age (study V72P10);
yoa: years of age;
vs: versus;
AEs: Adverse Events.

Less Common Drug Reactions Seen in Clinical Trials (<1%)

Adverse reactions (following primary immunization or additional dose) considered as being at least possibly related to vaccination have been categorized by frequency.

Frequencies are defined as follows:
Uncommon: ≥ 1/1,000 to < 1/100
Rare: ≥ 1/10,000 to < 1/1,000

Infants and Children (Less Than 2 Years of Age)

General disorders and administration site conditions
Uncommon: fever (≥40°C)

Nervous system disorders
Uncommon: seizures (including febrile seizures)

Skin and subcutaneous tissue disorders
Uncommon: eczema, urticaria

Vascular disorders
Uncommon: pallor (rare after booster)
Rare: Kawasaki syndrome

Post-market Adverse Drug Reactions

In addition to reports in clinical trials, worldwide voluntary reports of adverse reactions received for Bexsero since market introduction are listed below. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency

General disorders and administration site conditions
Blisters at or around the injection site

Immune system disorders
Allergic reactions (including anaphylactic reactions)

Nervous system disorders
Syncope or vasovagal responses to injection

Drug Interactions

Drug-Drug Interactions

BEXSERO can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella and varicella (see Part II, CLINICAL TRIALS, Immunogenicity Data, Concomitant use of BEXSERO with routine vaccines).

As higher percentages of subjects reported systemic reactions, including fever, change in eating habits, tenderness at the injection site and irritability, following BEXSERO given concomitantly with routine vaccines than after BEXSERO alone, separate vaccinations can be considered when possible. In addition, fever was mostly reported during the 1-4 days after vaccination with Bexsero alone and during the 5-28 days after the MMRV vaccination alone.
Prophylactic use of acetaminophen reduces the incidence and severity of fever without affecting the immunogenicity of either BEXSERO or most antigens of routine vaccines. The effect of antipyretics other than acetaminophen on the immune response has not been studied.

Concomitant administration of BEXSERO with vaccines other than those mentioned above has not been studied.

When given concomitantly with other vaccines, BEXSERO should be administered at different injection site

Drug-Lifestyle Interactions

BEXSERO has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section ADVERSE REACTIONS may temporarily affect the ability to drive or use machines.

Dosage and Administration

Dose of 0.5 mL.

Recommended Dose and Dosage Adjustment

Infants Aged 2 Months Through 5 Months

The recommended immunisation series consists of four doses, each of 0.5 mL. The primary infant series consists of three doses, given at 2, 4 and 6 months of age, followed by a fourth dose (booster)

The primary series can also be given at 2, 3 and 4 months of age, but the immune response to the NHBA antigen is lower (see Table 13)

With both schedules, a fourth dose (booster) is required in the second year of life between 12 and 23 months of age. It is preferred this dose be given early in the second year of life, whenever possible.

Unvaccinated Infants Aged 6 Months Through 11 Months

The vaccination schedule consists of three doses each of 0.5 mL with an interval of at least 2 months between the first and second dose. A third dose is required in the second year of life with an interval of at least 2 months between the second and third dose. The need for further booster doses has not been established.

Unvaccinated children aged 12 months through 23 months

The vaccination schedule consists of two doses, each of 0.5 mL, with an interval of at least 2 months between doses. The need for a booster dose after this vaccination schedule has not been established.

Children Aged 2 Years Through 10 Years

The vaccination schedule consists of two doses, each of 0.5 mL, with an interval of at least 2 months between doses. The need for a subsequent dose after this immunisation schedule has not been established.

Individuals Aged 11 Years Through 17 Years

The vaccination schedule consists of two doses, each of 0.5 mL, with an interval of at least 1 month between doses. The need for a subsequent dose after this vaccination schedule has not been established.

Administration

BEXSERO should be given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects.

Separate injection sites must be used if more than one vaccine is administered at the same time. The vaccine must not be injected intravenously, subcutaneously or intradermally and must not be mixed with other vaccines in the same syringe.

BEXSERO must not be mixed with other medicinal products.

Overdosage

Experience of overdose is limited. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.

For management of a suspected drug overdose, contact your regional Poison Control Centre

Action and Clinical Pharmacology

Epidemiology Data

IMD is an important cause of meningitis and septicemia, which can lead to mortality (9% in Canada), increasing with age, or permanent sequelae (11-19%) despite appropriate antimicrobial therapy. Pharyngeal carriage rates of meningococci are highest in adolescents (20-30%).

There are 13 diverse polysaccharide capsules but only A, B, C, W-135, and Y serogroups commonly cause IMD. Since the decline in serogroup C disease after the implementation of meningococcal conjugate C immunisation programs, serogroup B has become the leading cause of IMD in Canada. According to the 2013 Canadian Communicable Disease Report (1), serogroup B is increasing in distribution (57% of all serogroups) and incidence (0.4 per 100,000). The highest incidence of serogroup B occurs in infants under 1 year of age (80% of cases or 5.5per 100,000 in 2007, up to 6.16 per 100,000 in 2009), followed by children from 1 to 4 years of age (67% of cases or 1.28per 100,000 in 2007, up to 1.35 in 2008) (1, 2). The incidence in young children is higher than that of serogroup C before the implementation of serogroup C immunisation programs. Other peaks occur in 15 to 19 years (62% of cases or 0.8 per 100,000) and 20 to 24 years of age (71% of cases or 0.66 per 100,000). Since 2003, Quebec has seen the introduction and increase of a strain of serogroup B N. meningitidis identified as B:17:P1.19 sequence type ST-269 with 43 out of 198 (22%) serogroup B cases reported in Quйbec between 2002 and 2011 (2). From 2009 to 2011 in Quйbec, serogroup B has been responsible for 88% of all IMD cases reported to laboratory surveillance and 61% of all IMD deaths where 65% of serogroup B IMD are caused by this ST-269cc in 2011. During this period, serogroup B was responsible for 100% of laboratory confirmed IMD in infants <1 years of age, 94% in 1-24 year olds, 76% in 25-64 year olds and 58% in those ≥ 65 years of age (3).

The potential of BEXSERO to protect against diverse invasive serogroup B strains isolated in Canada was studied using the Meningococcal Antigen Typing System (MATS) that was specifically developed to estimate coverage by the primary antigens present in BEXSERO. The MATS was established to relate antigen profiles of different strains of meningococcal group B bacteria to killing of the strains in the serum bactericidal assay with human complement (hSBA). As the antigens, including NHBA, NadA, fHbp, and PorA P1.4, are variably expressed by different strains, meningococci that express them at sufficient levels are susceptible to killing by vaccine-elicited antibodies (4).

A survey of approximately 157 invasive serogroup B isolates collected during 2006-2009 by the IMPACT surveillance network (Immunization Monitoring Program ACTive) revealed that 66% of isolates had an appropriate type and sufficient antigen content and were predicted to be covered by BEXSERO, with empirical variability in coverage from 43% to 78%. The survey utilized the bactericidal thresholds that were derived using serum pools from 13-month old infants after 4 immunizations of BEXSERO at 2, 4, 6 and 12 months of age. Coverage for the Canadian hyper-endemic strains, the two most prevalent strains (sequence type ST-269 and ST-154) was 95% and 100%, with empirical variability in coverage ranging from 43% to 97% and 100% to 100%, respectively (5). As MATS coverage predictions are based on killing of meningococci by immune serum pools and not individual subject sera, this prediction is subject to certain limitations and its accuracy may only be verified upon vaccine use. The vaccine appears to provide coverage across a wide diversity of endemic strains and is not limited to protecting against one or two subtypes. At least 40% of isolates were covered by two or more vaccine antigens, with fHbp and NHBA contributing the most to vaccine coverage (5).

For epidemiology and further information specific to Canada, please consult Canada Communicable Disease Reports ACS-3 (April 2009) (6), ACS-4 (June 2009) (7) and ACS-1 (January 2013) (1), www.phac-aspc.gc.ca

Mechanism of Action

BEXSERO is a vaccine containing both purified, recombinant protein antigens and OMV derived from N. meningitidis. Protection against IMD is mediated mainly by bactericidal antibodies directed against components of the bacterium. Immunization with BEXSERO is intended to rais the titer of bactericidal antibodies that specifically bind the vaccine antigens fHbp, NadA, NHBA and PorA P1.4 (the immunodominant antigen present in the OMV component). Meningococci that express either the PorA P1.4 antigen or sufficient levels of any of the other antigens (NadA, fHbp, NHBA), defined as the positive bactericidal threshold, are predicted to be susceptible to killing by vaccine-elicited immune serum (see ACTION AND CLINICAL PHARMACOLOGY, Epidemiology Data).

Pharmacodynamics

Clinical Efficacy

No clinical efficacy studies have been undertaken with BEXSERO.
The efficacy of BEXSERO has been inferred by measuring bactericidal antibody responses to each of the vaccine antigens fHbp, NadA, NHBA and PorA P1.4, using a set of four meningococcal serogroup B reference strains (H44/76, 5/99, M10713 and NZ98/254, respectively). However, data are not available from all vaccine schedules using strain M10713. Two reference strains (strains H44/76 and 5/99) were selected for hSBA with high level expression of the antigens included in the vaccine, as compared to most of the circulating strains. These two strains could generate a higher percentage of subjects with hSBA ≥1:5 and higher GMTs than the strains with a low expression (if selected as the reference strains). Although the reference strains are intended to evaluate how well vaccinees mount a functional, antigen-specific immune response against the vaccine antigens, using the strains with high level of antigen expression could potentially result in a more favourable outcome than strains with low level of expression.

Bactericidal antibodies against these strains were measured by hSBA.

The studies of Goldschneider et al. demonstrated an inverse relationship between meningococcal disease incidence and prevalence of hSBA for serogroups B, C, and A (8, 9). The experience with outer membrane vesicle (OMV) vaccines supports this observation where the percentage of subjects with SBA ≥4 was similar to the estimated efficacy rates (10). It is generally recognised that the surrogate of protection for serogroup B meningococci is the hSBA even though the immune responses are not directed against capsular polysaccharide antigens (11, 12).

Immunogenicity was evaluated in randomized, multicenter, clinical trials that enrolled infants, children (less than 2 years of age), adolescents and adults (see Part II, CLINICAL TRIALS).

Pharmacokinetics

Evaluation of pharmacokinetic properties is not required for vaccines; therefore, no pharmacokinetic studies have been conducted with the vaccine.

Duration of Effect

The duration of post vaccination immune status has not been established.

Storage and Stability

Store in a refrigerator at 2°C to 8°C.
Do not freeze. Do not use vaccine that may have been frozen.
Protect the vaccine from light.

The expiry date of the vaccine is indicated on the label and packaging.
Do not use the vaccine after the expiry date shown on the label.

In the absence of compatibility studies, BEXSERO must not be mixed with other medicinal products.

Special Handling Instructions

A fine off-white deposit may form when the product stands for a long period.
Shake the vaccine well before use to form a homogeneous suspension. The vaccine should be visually inspected for particulate matter and discoloration prior to administration.

In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

Any unused product or waste material should be disposed in accordance with local requirements.

Dosage Forms, Composition and Packaging

Dosage Forms

BEXSERO is a white opalescent liquid suspension for intramuscular injection.

Composition

1 dose (0.5 mL) contains:

Recombinant Neisseria meningitidis serogroup B NHBA fusion protein1, 2, 3 50 micrograms
Recombinant Neisseria meningitidis serogroup B NadA protein1, 2, 3 50 micrograms
Recombinant Neisseria meningitidis serogroup B fHbp fusion protein1, 2, 3 50 micrograms
Outer membrane vesicles (OMV) from Neisseria meningitidis serogroup B strain NZ98/254 measured as amount of total protein containing the PorA P1.42

25 micrograms

1Produced in E. coli by recombinant DNA technology.

2Adsorbed on aluminum hydroxide (0.5 mg Al+3).

3NHBA (Neisseria Heparin Binding Antigen), NadA (Neisserial adhesin A), fHbp (factor H binding protein).

Additional excipients
Sodium chloride, histidine, sucrose, water for injections.

Packaging

BEXSERO is supplied as a 0.5 mL suspension in a pre-filled syringe (Type I glass).

The tip cap of the syringe may contain natural rubber latex (see section WARNINGS AND PRECAUTIONS).

Packs of 1 or 10 syringes, supplied with or without needles. Not all pack sizes may be marketed.